Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807, Taiwan
Location status: Recruiting
NCT Number: NCT03217578
Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA. The dried blood spots of routine newborn screening samples will be used to test if neonates have lost 2 copies of SMN1 gene. If neonates have positive SMA screening test, further confirmation with multiplex ligation-dependent probe amplification (MLPA) test and prospective motor function monitoring including physical and neurological examinations will be proved to make SMA confirmation. For any confirmed SMA patient, genetic counseling and standard of care will be proved.
Interested in participating?
Request Info0 week–2 week
All sexes
Observational
Kaohsiung City, 807, Taiwan
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Parents or legal guardian do not agree to perform SMA newborn screening.
Time frame: 3 years
Neonates with positive SMA newborn screening will be confirmed by multiplex ligation-dependent probe amplification (MLPA) test
Time frame: 3 years
Neonates with confirmed the deletion of 2 copies of SMN1 gene by MLPA test will be followed till SMA symptoms appear.
Contact information is provided by the study sponsor or research team.
Kaohsiung Medical University Chung-Ho Memorial Hospital
Other
Study on the Neonatal Screening of Spinal Muscular Atrophy
Acronym: SMA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06532474
Central Nervous System Diseases, Motor Neuron Disease
Memphis, Tennessee, United States
View Trial DetailsNCT06955897
Behavior, Central Nervous System Diseases
New York, United States
View Trial DetailsNCT07047144
Anti-myostatin, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07444476
Central Nervous System Diseases, Motor Neuron Disease
Norfolk, Virginia, United States
View Trial Details